PMWC 2019 Silicon Valley
Luminary & Pioneer Awards
The PMWC Luminary Award recognizes recent contributions of preeminent figures who have accelerated personalized medicine into the clinical marketplace. The PMWC Pioneer Award is given to rare individuals who presaged the advent of personalized medicine when less evolved technology and encouragement from peers existed, but still made major advances in the field.
This year, for the Luminary Award, PMWC will be honoring Carl June for developing CAR-T therapy (the world’s first gene-based cancer therapy), Sharon Terry for inciting the movement to build systems for individuals to access and share health data, and Feng Zhang for spearheading the development of optogenetics and CRISPR. For the Pioneer Award, PMWC will be recognizing George Yancopoulos for developing foundational technologies designed to invent groundbreaking therapies.
Awardees
Date & Agenda
When: January 20th at 6:00-8:00pm
Agenda: Award Reception Agenda
Where: PMWC Venue – Track 2 (Great America Ballroom)
Suggested dress: Cocktail attire
RSVP AND SEPARATE REGISTRATION REQUIRED. SEND INQUIRIES BY 1/4/19 TO [email protected] TO SEE IF SPACE IS AVAILABLE.
Past Luminary Award Recipients
Emmanuelle Charpentier
2018
Pioneered the CRISPR-CAS9 Genome Editing Technology
Jennifer Doudna
2017
Pioneered the Groundbreaking Crispr-Cas9 Genome Editing Technology
Edward F. Chang
2017
Pioneer in Human Brain Circuit Mapping to Advance Precision Neuropathology
James Allison
2017
Pioneered Cancer Immunotherapy Through Discovery of the Immune Checkpoint Blockade
Roger Perlmutter
2016
Expedited Development of Groundbreaking Therapies
Laura Esserman
2016
Breast Cancer Treatment Paradigm Shifter
Ron Davis
2015
Developed R-loop Technique of Electron Microscopy
Jay Flatley
2014
Established Illumina as the leader in sequence technology
Janet Woodcock
2013
FDA Director, fast-tracked targeted drugs through FDA approval
Brian Druker
2012
Co-inventor, blockbuster drug, Gleevec
George Church
2011
Contributions to the sequencing of genomes and interpreting such data; In Neuroscience he established a “functional connectome”
Lee Hood
2010
Inventions included the automated DNA sequencer and a tool for synthesizing DNA
Past Pioneer Award Recipients
Ronald Levy
2018
Pioneered the concept of antibodies being used as personalized anticancer drugs
Sir John Bell
2018
Leading Genetic and Genomic Research Initiatives that Enable Precision Medicine in the UK and Globally
Alan Ashworth
2018
Co-discovered the BRCA2 gene mutation and made discoveries leading to PARP inhibition in breast and other cancers
Steve Quake
2017
Steve Quake has pioneered innovative approaches to biological measurement
Irv Weissman
2016
Pioneer in Regenerative Medicine & Cancer Stem Cells
Ralph Snyderman
2016
Widely recognized as “Father of Personalized Medicine”
Craig Venter
2015
1st Draft Human Gen., 1st Complete Diploid Human Gen., and 1st Synth. Bact. Cell
Dennis Lo
2015
Discovered That An Unborn Fetus Releases Fetal DNA Into Maternal Plasma
Yuet Wain Kan
2014
The first to establish that a single DNA mutation could lead to a human disease, and the first to diagnose a human disease by using DNA
Michael Hayden
2014 – Israel
Developer, First Predictive Test for Huntington’s Disease
Kim Popovits
2013 – Israel
Launched both earliest genetically-targeted therapy and molecular diagnostic assay
Most Promising Company Award
The PMWC Most Promising Company Competition has accompanied PMWC since 2009 with the goal to assist “rising star” startups in Diagnostics, Therapeutics, and Health Tech to increase their visibility, provide them with a platform to present to a group of leading investors, as well as to potential clients and partners so they can succeed on their path forward.
Abreos Biosciences
Abreos Biosciences is a precision medicine company in San Diego, CA developing laboratory-based and near-patient tests for precision dosing of biologic drugs. Abreos has cultivated a diverse portfolio of Veritope™ tests that allow for direct monitoring of blood concentrations of monoclonal antibody drugs (novel or biosimilar). Website: abreos.com
Immusoft
Immusoft’s mission is re-program patient cells into miniature drug factories that engraft and survive for decades in the body. Website: immusoft.com
Two Pore Guys
Two Pore Guys created a solid-state nanopore-based diagnostic testing platform that can detect nucleic acids, proteins and other analytes with comparable performance of lab equipment, in a glucometer-style system. Website: twoporeguys.com
Gritstone Oncology
Every patient’s tumor is molecularly unique – Gritstone Oncology deploys a proprietary tumor antigen prediction model based upon patient tumor sequencing/mass spectrometry to deliver antigens as personalized therapeutic vaccine alongside checkpoint inhibitors. Website: gritstoneoncology.com
HEALTHMYNE
HealthMyne is an imaging informatics company dedicated to transforming patient care by enabling image data mining within the clinical workflow. Built on an FDA-cleared diagnostic platform, HealthMyne tools will increase radiologist efficiency by automating both data capture and structured reports. Website: healthmyne.com
INSILICO MEDICINE
Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Website: insilicomedicine.com
ACCEL DIAGNOSTICS
AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests at any time and any place. The patented pScreen™ platform technology employs a single-use blood test the size of a credit card in tandem with a smartphone application to quickly detect disease-specific biomarker levels. Website: acceldx.com
T2 BIOSYSTEMS
T2 Biosystems is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. Their new class of clinical diagnostics powered by T2MR is the world’s first direct detection technology that delivers superior sensitivity at unmatched speed to guide more effective clinical decision-making. IPO, Aug. 2014. Website: t2biosystems.com
ELMINDA
ElMindA has developed the BNA™ technology platform, which for the first time allows high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain at work, capturing information on the composition, connectivity, synchronization and operation of brain networks. Website: elminda.com
HORIZON DISCOVERY
Horizon Discovery Limited has developed a translational genomics platform and drug discovery toolbox that enables the development of new therapies targeted at the genetic features that drive an individual’s cancer. IPO, March 2014. Website: horizondiscovery.com
QUANTALIFE
QuantaLife provides advanced genetic analysis systems for research. QuantaLife has commercialized the Droplet Digital™ (ddPCR) system, the most accurate genetic analysis platform available today. The system is the first cost-effective, high-resolution platform available for the validation of next-generation sequencing discoveries. With the ddPCR system, researchers can explore complex genetic landscapes in high-definition, discover new disease associations, and define a new category of improved molecular diagnostic tests. Acquired by Bio-Rad, October 2011. Website: bio-rad.com
APPLIED IMMUNE TECHNOLOGIES
Applied Immune Technologies’ (AIT) core technology platforms encompass the identification and validation of novel MHC-based targets, as well as development of therapeutic Human Recombinant T-Cell Receptor-Like (TCRL) antibodies with the unique ability to bind with these intracellular peptide/MHC complexes with the specificity of cytotoxic T-cell killer cells. Acquired by Adicet Bio, January 2016. Website: tcrl.co.il
BOSTON HEART LAB
Boston Heart Diagnostics is a heart health management company providing integrated diagnostic and patient management solutions that are advancing cardiovascular disease risk assessment, monitoring and treatment. The Company’s goal is to predict, prevent, manage and reverse cardiovascular disease by improving patient assessment and management. Acquired by Eurofins Scientific, December 2014. Website: bostonheartdiagnostics.com
